Susie Harborth

Susie Harborth is Chief Financial Officer at Mission BioCapital. Prior companies include BioInnovation Captial, BioLabs, GnuBIO, Boston Heart Diagnostics, Cequent Pharmaceuticals and Leerink Swann. At GnuBIO, Susie lead finance & operations and was responsible for strategy, HR, facilities and investor relations. In 2013, she was named a “Women to Watch” by Boston Business Journal and Mass High Tech. Prior to joining GnuBIO, Susie was Vice President, Business Operations at Cequent Pharmaceuticals (acquired by Marina Biotech) where she was responsible for financial management, human resources, IT, facilities, legal, vendor and investor relations. She developed the initial business infrastructure for Boston Heart Diagnostics (BHDx), a Bain Capital Ventures portfolio company, and provides operational support to a variety of start-ups including companies in molecular diagnostics, healthcare IT, SaaS, consumer and financial services industries. Prior to Cequent, Susie focused on public life science companies at Leerink Swann & Co, where she was responsible for operations of the institutional sales trading department. In addition to her operational roles, Susie has held various financial, marketing, and administrative positions with Harmony Software (merged with Vigilance, Inc), Crimson Ventures and Alar Staffing Corp. She received her masters in biology (ALM) from Harvard University and an undergraduate degree in business administration/finance from California State University, Long Beach. Her graduate research was conducted at Massachusetts General Hospital (MGH) in the field of breast cancer diagnostics using HRMAS spectroscopy.